Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.37 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | CCND1 | P24385 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556505 | 0.82 | KDM4E (0.37) | FFAR1CDK4CCND1CDK2KMT2A | |
| SCHEMBL555819 | 0.74 | MTNR1A (0.54) | KMT2AKDM4EMTNR1AMTNR1B | |
| SCHEMBL16333188 | 0.73 | HTR1A (0.54) | CDK4CCND1CDK2KMT2ANPC1 | |
| SCHEMBL27730951 | 0.72 | TAAR1 (0.44) | CDK4CCND1CDK2KMT2AKDM4E | |
| SCHEMBL555604 | 0.72 | TAAR1 (0.62) | FFAR1CDK4CCND1KMT2AKDM4E | |
| SCHEMBL18422574 | 0.72 | TAAR1 (0.62) | CDK4CCND1KMT2AALDH1A1NPC1 | |
| SCHEMBL27759121 | 0.72 | SIGMAR1 (0.47) | CDK4CCND1CDK2KMT2AKDM4E | |
| SCHEMBL23925502 | 0.70 | AOC3 (0.61) | CDK4CCND1KMT2AKDM4EALDH1A1 | |
| SCHEMBL8751582 | 0.70 | HCRTR1 (0.54) | KMT2AKDM4EMTNR1AMTNR1B | |
| SCHEMBL1520363 | 0.69 | KMT2A (0.59) | KMT2ANPC1RAB9ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | FFAR1 1735/4885CDK4 998/4885CCND1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.